Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21784727 | 0.90 | CYP2D6 (0.40) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL23842473 | 0.89 | CYP19A1 (0.41) | CYP19A1CYP2D6HSP90AA1CYP3A4 | |
| SCHEMBL18415044 | 0.83 | FAAH (0.38) | CYP19A1CYP2D6CYP3A4FAAH | |
| SCHEMBL23842514 | 0.82 | CYP2D6 (0.41) | CYP19A1CYP2D6HSP90AA1ESR1ESR2 | |
| SCHEMBL21370103 | 0.81 | CYP19A1 (0.39) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL21370147 | 0.80 | CYP19A1 (0.38) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL24872011 | 0.79 | FAAH (0.40) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL24871950 | 0.79 | FAAH (0.40) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL22828519 | 0.79 | FAAH (0.40) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH | |
| SCHEMBL18557088 | 0.79 | FAAH (0.40) | CYP19A1CYP2D6HSP90AA1CYP3A4FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NOVARTIS AG (CH) | 2018-07-03 | — | — | US | disclosed |
| US-9902722-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170183340-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-06-29 | — | — | US | disclosed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | CYP19A1 483/4885CYP2D6 1343/4885HSP90AA1 567/4885 |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | CYP19A1 3222/4885CYP2D6 638/4885HSP90AA1 1478/4885 |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | CYP19A1 2344/4885CYP2D6 48/4885HSP90AA1 1958/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | CYP19A1 483/4885CYP2D6 1343/4885HSP90AA1 567/4885 |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | CYP19A1 2344/4885CYP2D6 48/4885HSP90AA1 1958/4885 |
| US-20170183340-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | CYP19A1 3940/4885CYP2D6 4537/4885HSP90AA1 1232/4885 |
| US-10011599-B2 | Compounds and compositions as inhibitors of MEK | NRAS, BRAF, KRAS | CYP19A1 499/4885CYP2D6 1488/4885HSP90AA1 3093/4885 |
| US-20170183348-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK | NRAS, BRAF, KRAS | CYP19A1 499/4885CYP2D6 1488/4885HSP90AA1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.